US5869648A - Process for the purification of a 3-cephem-4-carboxylic acid derivative - Google Patents
Process for the purification of a 3-cephem-4-carboxylic acid derivative Download PDFInfo
- Publication number
- US5869648A US5869648A US08/466,306 US46630695A US5869648A US 5869648 A US5869648 A US 5869648A US 46630695 A US46630695 A US 46630695A US 5869648 A US5869648 A US 5869648A
- Authority
- US
- United States
- Prior art keywords
- formula
- carboxylic acid
- cephem
- amino
- propen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
Definitions
- the invention relates to methods of reducing the E-(trans) isomer amount in the Z/E (cis/trans) 7-amino-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid of formula I ##STR1##
- the Z-isomer, 7-amino-3- (Z)-1-propen-1-yl!-3-cephem-4-carboxylic acid of formula Ia ##STR2## is a central intermediate for the production of highly effective broad-band antibiotics, for example cefprozil and BAY v 3522 of formulae ##STR3## It is known that the Z-(or cis-)configuration represents the characteristic which determines the advantageous antibacterial properties of cephalosporin end products in the Gram negative range. Consequently, an active substance with the smallest possible proportion of E-(or trans-) isomer is desired for optimum efficiency. For example the undesired E-isomer in cefprozil should not exceed 11% according to the U.S. Pharmocopeia.
- Z/E 7-amino-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid of formula I with a too high E proportion may be converted into compound of formula I with low E content via the hydrochloride or a metal or amine salt of the compound of formula I or by adsorption chromatography of the compound of formula I.
- the invention comprises simple and efficient methods of depleting 7-amino-3- (E)-1-propen-1-yl!-3-cephem-4-carboxylic acid in Z/E mixtures of 7-amino-3- 1-propen-1-yl!-3-cephem-4-carboxylic acid by
- Process a may be carried out as follows:
- hydrochloride is carried out in a solvent or solvent mixture, in which the Z- and E-isomers of formula I' have different solubilities.
- the hydrochloride of formula I' may be formed both in protic and in aprotic medium. If operating in an aqueous system, the Z/E mixture of the compound of formula I is dissolved in water or an aqueous organic solvent such as aqueous alcohol, e.g. isopropanol, aqueous acetone or acetonitrile, by adding hydrochloric acid, and precipitating the hydrochloride by addition of an organic counter solvent.
- Suitable organic counter solvents are in particular organic nitriles such as acetonitrile; ketones, e.g. acetone; alcohols, e.g.
- the Z/E mixture of formula I is dissolved in concentrated form in an alcohol, e.g. methanol or isopropanol, with water-free hydrochloric acid, and is then diluted with one of the above mentioned counter solvents, whereby the crystalline Z-enriched product is crystallized out.
- the hydrochloride of formula I' may be suspended or dissolved in a solvent or solvent mixture in which the E-isomer of 7-amino-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid hydrochloride is better soluble than the corresponding Z-isomer.
- Suitable solvents are alcohols, e.g. methanol, ethanol or isopropanol or a sulfone, e.g. sulfolane.
- Precipitation is then induced by e.g. adjustment of the solubility product of the Z- or E-isomer optionally by addition of one of the above mentioned counter solvent, whereby the hydrochloride of compound of formula I' with a reduced E-amount is obtained.
- the hydrochloride which is thereby much improved in its Z/E ratio may subsequently be converted again into the compound of formula I in conventional manner, e.g. by means of pH adjustment in water to the approximate isoelectric point.
- Compounds of formula I' may be prepared as described by the processes herein containing various amounts of Z/E isomers, e.g. in a ratio of 91:9 or less, 92:8 or less, conveniently 94:6 or more, or 95:5 or less; 97:3 or less; 99:1 or less.
- the crystalline hydrochloride of formula I' is new and also form part of the invention.
- the hydrochloride of formula I' having a Z/E ratio of at least 91:9 or less is also new and form part of the invention.
- Process b may be effected as follows:
- the compounds of formula II may be formed in a protic or in an aprotic medium. If operating in an aqueous system, the Z/E mixture of the compound of formula I is dissolved in water or an aqueous organic solvent such as acetone or an alcohol e.g. isopropanol, by adding a base, such as lithium, sodium or potassium base, e.g. hydroxide, carbonate or hydrogencarbonate or a nitrogen containing base such as ammonia. Then an amine of formula IV or a lithium, sodium or potassium source is added and the solution optionally diluted with an organic counter solvent, whereby a compound of formula II precipitates.
- a base such as lithium, sodium or potassium base, e.g. hydroxide, carbonate or hydrogencarbonate or a nitrogen containing base such as ammonia.
- the Z/E mixture of the compound of formula I may be suspended in water, or an aqueous organic solvent such as acetone or an alcohol, e.g. isopropanol, the suspension is treated first with a lithium, sodium or potassium source or ammonia or a compound of formula IV and then with an organic counter solvent and optionally adjusting the pH with lithium, natrium or potassium base, e.g. hydroxide, carbonate or bicarbonate in case a lithium, sodium or potassium source such as lithium, sodium or potassium acetate is used.
- an aqueous organic solvent such as acetone or an alcohol, e.g. isopropanol
- Typical lithium, sodium or potassium sources include lithium, sodium or potassium salts of carboxylic acids, such as sodium or potassium acetate or lithium, sodium or potassium 2-ethylhexanoate.
- the Z/E mixture of formula I is suspended in an organic solvent, adding a base of formula IV and optionally diluting with a counter solvent or a mixture of counter solvents.
- organic solvents are amides, e.g. dimethylformamide; sulfoxide, e.g. dimethylsulfoxide; sulfone, e.g. sulfolane; halogenated hydrocarbons, e.g. dichloromethane; ketones, e.g. acetone; esters; ethers, e.g. tetrahydrofuran; alcohols, e.g.
- methanol ethanol
- ethanol one of the isomeric propanols or butanols
- nitriles e.g. acetonitrile or mixtures of these solvents.
- Further solvents may be added in admixture such as diethyl ether or tert.butyl methyl ether.
- R 1 with R 2 and the nitrogen atom signify a 5- or 6-membered heterocycle, containing optionally 1 or 2 additional heteroatoms, these are preferably oxygen or sulphur atoms.
- heterocycle are morpholine, N-methyl-morpholine, oxazolidine or thiazolidine.
- Preferred examples of compounds of formula IV are dicyclohexylamine and 2,4,4-trimethylpentyl-2-amine.
- the compounds of formula II may be easily converted into compounds of formula I with a reduced E content, by dissolving or suspending a compound of formula II in water and by acidifying, whereby the nitrogen containing base may optionally be removed by extraction in a first alkaline step or kept in solution by addition of an organic solvent such as an alcohol or a ketone, when the base is forming a salt, which is poorly soluble in water.
- an organic solvent such as an alcohol or a ketone
- Process b) has several advantages. Compounds of formula II are easily precipitated and crystallized. Process b) is especially advantageous, when applied to Z/E mixtures of formula I with a high E-content and/or containing by-products e.g. those obtained from mother liquors, e.g. from process a) or early eluting fractions from process c) containing by-products, effording products with a low E-content and high purity (see Example 4b). The fact that the process is applicable to products derived from mother liquors has also the advantage of an improved total yield.
- Processes a) and b) may be optionally repeated or compounds of formula II may be converted into the compound of formula I' in order to obtain the desired Z/E ratio.
- Process c) may be carried out as follows:
- Adsorbents include activated carbon, e.g. Norit CG-1, SX-plus, C-granular or Cecarbon GAC 40; adsorption resins such as HP-20, HP-21 or SP 207 (from e.g. Mitsubishi); XAD-1180, XAD-1600 or XAD 16 (from e.g. Rohm-Haas) or Amberchrome CG 161 (from e.g. Toso-Haas).
- the adsorption resin is XAD-1600 or Amberchrome CG 161. Elution is effected with water.
- the E-isomer has a better adsorption than the Z-isomer and thus is slower eluted as the Z-isomer.
- the first eluted fractions contain therefore mainly the Z-isomer, whereas the latest fractions contain mainly the E-isomer.
- the desired product may then be obtained by adjusting the pH value close to the isoelectric point, i.e. to 2.5-4.5, preferably to 3.0-3.7, whereby crystallization occurs.
- products with a very low amount of E-isomer ( ⁇ 3%) or products with an E-isomer of 7-9% are obtained.
- the amount of the adsorbent depends on the desired dissolution rate and the Z/E ratio of the starting compound of formula I.
- Process c) represents a very simple and economical method.
- the adsorbents may be regenerated.
- the elution is effected with water, no organic eluants are used.
- the apparative equipment is simple. No gradient elution or stepwise elution and no changes of pH are necessary.
- Processes a), b) and c) are suitable for industrial scale.
- a mixture of 15 ml of 5N HCl in methanol and 30 ml of acetonitrile is cooled with ice water.
- a solution is obtained.
- the cooling bath is removed and the solution is slowly diluted over the course of 30 minutes with the dropwise addition of 300 ml of acetonitrile.
- the solution is seeded with PACA.hydrochloride.
- the resultant crystal suspension is stirred for a further one hour whilst cooling with ice.
- the product is isolated through a suction filter, washed twice, each time with 40 ml of acetonitrile, and dried in a vacuum drying chamber.
- a suspension of 10 g of PACA with a Z/E ratio of 86/14 (HPLC content 93.4%) in 50 ml dichloromethane is treated with 12.4 ml of dicyclohexylamine, whereby a slightly clouded solution results. Crystallisation is starting and the suspension is cooled, the product filtered off, washed with cold dichloromethane and dried in a vacuum chamber.
- a suspension of 10 g PACA with a Z/E ratio 86.3/13.7 (HPLC content 95%) in a mixture of 80 ml acetone and 40 ml water is treated with 7.6 ml tert.-octylamine. Further 520 ml of acetone are added. The obtained suspension is stirred for 2 hours at room temperature.
- the tert.octylammonium (2,4,4-trimethylpentyl-2)ammonium! salt of PACA is filtered off, washed with acetone and dried in a vacuum chamber.
- PACA-dicyclohexylammonium salt (E-content 7.6%, PACA-content 53.11%) are added to 4000 ml water of 30°. After about 2 minutes a solution results, to which 5 g activated carbon are added. The mixture is stirred for 10 minutes, the carbon is filtered off and washed with 250 ml water. The pH of the combined filtrate and washing is slowly adjusted to 3.5 with 5N sulfuric acid. The obtained crystall suspension is cooled in an ice-bath and stirred for 2 hours while cooling. The product is filtered off, washed sequentially with total 200 ml water, 100 ml water/acetone (1:1) and 250 ml acetone. The product is dried in a vacuum chamber at 400°.
- the filtrates are collected in fractions of each about 40 ml.
- the first 2 fractions do not contain the product (HPLC control).
- Fractions 3 to inclusive 7 contain mainly the Z-PACA and only a very small amount of E-PACA and are therefore combined. These 230 ml are adjusted with 2N HCl to pH 3.4, whereby the product crystallises.
- the product is filtered off, washed with water and acetone and dried to yield 2.8 g PACA (content 96.7%) and containing ⁇ 0.1% E isomer.
- the resin is regenerated by elution with aqueous isopropanol to which some ammonia is added, rinsed with water and may be again employed.
- the adsorption resin is thereafter regenerated as described in EXAMPLE 9.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/466,306 US5869648A (en) | 1992-02-05 | 1995-06-06 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
US09/190,200 US6136967A (en) | 1992-02-05 | 1998-11-12 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
US09/564,833 US6333409B1 (en) | 1992-02-05 | 2000-05-04 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0019192A AT399876B (de) | 1992-02-05 | 1992-02-05 | Verfahren zur abreicherung von 7-amino-3-((e)-1- propen-1-yl)-3-cephem-4-carbonsäure |
ATA191/92 | 1992-02-05 | ||
GB929225666A GB9225666D0 (en) | 1992-12-09 | 1992-12-09 | Process for the depletion of 7-amino-3-((e)-propen-1-yl)-3-cephem-4-carboxylic acid |
GB9225666 | 1992-12-09 | ||
PCT/EP1992/002965 WO1993016084A1 (en) | 1992-02-05 | 1992-12-21 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
US28451594A | 1994-08-05 | 1994-08-05 | |
US08/466,306 US5869648A (en) | 1992-02-05 | 1995-06-06 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1992/002965 Continuation WO1993016084A1 (en) | 1992-02-05 | 1992-12-21 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
US28451594A Continuation | 1992-02-05 | 1994-08-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/190,200 Division US6136967A (en) | 1992-02-05 | 1998-11-12 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
US5869648A true US5869648A (en) | 1999-02-09 |
Family
ID=25591794
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/466,306 Expired - Fee Related US5869648A (en) | 1992-02-05 | 1995-06-06 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
US09/190,200 Expired - Lifetime US6136967A (en) | 1992-02-05 | 1998-11-12 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
US09/564,833 Expired - Fee Related US6333409B1 (en) | 1992-02-05 | 2000-05-04 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/190,200 Expired - Lifetime US6136967A (en) | 1992-02-05 | 1998-11-12 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
US09/564,833 Expired - Fee Related US6333409B1 (en) | 1992-02-05 | 2000-05-04 | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
Country Status (14)
Country | Link |
---|---|
US (3) | US5869648A (ru) |
EP (2) | EP1103555B1 (ru) |
JP (1) | JP2825655B2 (ru) |
KR (1) | KR950700311A (ru) |
AT (2) | ATE253583T1 (ru) |
CA (1) | CA2124322C (ru) |
DE (2) | DE69233249T2 (ru) |
DK (1) | DK0630380T3 (ru) |
ES (2) | ES2162812T3 (ru) |
GR (1) | GR3036985T3 (ru) |
PT (1) | PT630380E (ru) |
SG (1) | SG48415A1 (ru) |
TW (1) | TW230775B (ru) |
WO (1) | WO1993016084A1 (ru) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6350869B1 (en) * | 1997-04-04 | 2002-02-26 | Biochemie Gesellschaft M.B.H. | Crystalline amine salt of cefdinir |
WO2004033464A1 (en) * | 2002-10-08 | 2004-04-22 | Ranbaxy Laboratories Limited | Process for the preparation of (z)-isomer enriched 7-amino-3-propen-1-yl-3-cephem-4- carboxylic acid |
WO2004039812A1 (en) * | 2002-10-30 | 2004-05-13 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of 3-propenyl cephalosporin dmf solvate |
WO2005100369A1 (en) * | 2004-04-13 | 2005-10-27 | Ranbaxy Laboratories Limited | Depletion of e-isomers in preparation of z-enriched 3-(2-substituted vinyl) cephalosporins |
US20060025586A1 (en) * | 2002-08-13 | 2006-02-02 | Peter Kremminger | Cefdinir intermediate |
US20060122165A1 (en) * | 2004-12-07 | 2006-06-08 | Otto Daemon | Crystalline cefdinir |
US20070128268A1 (en) * | 2005-12-07 | 2007-06-07 | Herwig Jennewein | Pharmaceutical compositions comprising an antibiotic |
US20070270586A1 (en) * | 2003-03-24 | 2007-11-22 | Eiji Imai | Novel crystal of 7-[2-[(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof |
US20110225507A1 (en) * | 2010-03-15 | 2011-09-15 | Gmc Software Ag | Method and devices for generating two-dimensional visual objects |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69427312T2 (de) | 1993-11-17 | 2001-08-23 | Biochemie Ges.M.B.H., Kundl | Trennung von Cephalosporinisomeren |
US5648378A (en) * | 1995-06-07 | 1997-07-15 | Research Corporation Technologies, Inc. | 2-iminochromene derivatives as inhibitors of protein tyrosine kinase |
AT403049B (de) | 1995-08-14 | 1997-10-27 | Biochemie Gmbh | Abreicherung von 7-adca in 3-vinyl-aca |
AT406773B (de) * | 1998-04-02 | 2000-08-25 | Biochemie Gmbh | Neues salz von 7-(2-(aminothiazol-4yl)-2- |
GB0118764D0 (en) * | 2001-08-01 | 2001-09-26 | Biochemie Gmbh | Organic compounds |
JP4046708B2 (ja) * | 2004-06-04 | 2008-02-13 | 明治製菓株式会社 | 3−アルケニルセフェム化合物の製造方法 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3769277A (en) * | 1970-01-23 | 1973-10-30 | Glaxo Lab Ltd | Preparation of delta3-4 carboxy cephalosporins having a 3-vinyl or substituted 3-vinyl group |
US4065620A (en) * | 1971-06-14 | 1977-12-27 | Eli Lilly And Company | 3-(Substituted) vinyl cephalosporins |
US4107431A (en) * | 1970-01-23 | 1978-08-15 | Glaxo Laboratories Limited | Δ3 -3-Vinyl or substituted vinyl-4-carboxy cephalosporins |
US4110534A (en) * | 1970-01-23 | 1978-08-29 | Glaxo Laboratories Limited | Process for the preparation of 3-vinyl and substituted vinyl cephalosporins |
FR2540117A1 (fr) * | 1983-01-28 | 1984-08-03 | Bristol Myers Co | Vinylcephalosporines substituees |
GB2173798A (en) * | 1985-04-22 | 1986-10-22 | Bristol Myers Co | Cephalosporanic acid derivatives |
GB2178032A (en) * | 1985-06-24 | 1987-02-04 | Bristol Myers Co | Cephalosporanic acid derivatives |
US4694079A (en) * | 1985-07-29 | 1987-09-15 | Bristol-Myers Company | 3-propenyl cephalosporin solvates |
US4727070A (en) * | 1985-11-25 | 1988-02-23 | Bristol-Myers Company | 3-Propenzl cephalosporin isomer separation process and derivative |
EP0292806A2 (de) * | 1987-05-26 | 1988-11-30 | Bayer Ag | Substituierte Vinylcephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP0304036A2 (en) * | 1987-08-17 | 1989-02-22 | Bristol-Myers Squibb Company | 3-(substituted)propenyl-7-(aminothiazolylacetamido)ceph-3-em-4-carboxylic acids and esters thereof |
US4847373A (en) * | 1987-02-26 | 1989-07-11 | Bristol-Myers Company | Production of 3-allyl- and 3-butenyl-3-cephems |
EP0355821A2 (en) * | 1988-08-23 | 1990-02-28 | Bristol-Myers Squibb Company | A process for preparing cephem prodrug esters |
EP0421219A2 (de) * | 1989-10-03 | 1991-04-10 | Bayer Ag | Verfahren zur Herstellung von 7-Amino-3-[(Z)-1-propen-1-yl]-3-cephem-4-carbonsäure |
EP0472060A2 (en) * | 1990-08-23 | 1992-02-26 | Bristol-Myers Squibb Company | Antibiotic c-7 catechol-subtituted cephalosporin compounds, compositions, and use thereof |
EP0503453A2 (en) * | 1991-03-08 | 1992-09-16 | Biochemie Gesellschaft M.B.H. | New process for the production of cephalosporines and novel intermediates in this process |
-
1992
- 1992-12-21 PT PT93901714T patent/PT630380E/pt unknown
- 1992-12-21 ES ES93901714T patent/ES2162812T3/es not_active Expired - Lifetime
- 1992-12-21 JP JP5513698A patent/JP2825655B2/ja not_active Expired - Lifetime
- 1992-12-21 AT AT01104309T patent/ATE253583T1/de not_active IP Right Cessation
- 1992-12-21 EP EP01104309A patent/EP1103555B1/en not_active Expired - Lifetime
- 1992-12-21 CA CA002124322A patent/CA2124322C/en not_active Expired - Fee Related
- 1992-12-21 DK DK93901714T patent/DK0630380T3/da not_active Application Discontinuation
- 1992-12-21 DE DE69233249T patent/DE69233249T2/de not_active Expired - Fee Related
- 1992-12-21 DE DE69232048T patent/DE69232048T2/de not_active Expired - Fee Related
- 1992-12-21 SG SG1996009496A patent/SG48415A1/en unknown
- 1992-12-21 AT AT93901714T patent/ATE205214T1/de not_active IP Right Cessation
- 1992-12-21 WO PCT/EP1992/002965 patent/WO1993016084A1/en active IP Right Grant
- 1992-12-21 ES ES01104309T patent/ES2210047T3/es not_active Expired - Lifetime
- 1992-12-21 KR KR1019940702673A patent/KR950700311A/ko not_active IP Right Cessation
- 1992-12-21 EP EP93901714A patent/EP0630380B1/en not_active Expired - Lifetime
- 1992-12-29 TW TW081110453A patent/TW230775B/zh not_active IP Right Cessation
-
1995
- 1995-06-06 US US08/466,306 patent/US5869648A/en not_active Expired - Fee Related
-
1998
- 1998-11-12 US US09/190,200 patent/US6136967A/en not_active Expired - Lifetime
-
2000
- 2000-05-04 US US09/564,833 patent/US6333409B1/en not_active Expired - Fee Related
-
2001
- 2001-10-23 GR GR20010401855T patent/GR3036985T3/el not_active IP Right Cessation
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3769277A (en) * | 1970-01-23 | 1973-10-30 | Glaxo Lab Ltd | Preparation of delta3-4 carboxy cephalosporins having a 3-vinyl or substituted 3-vinyl group |
US4107431A (en) * | 1970-01-23 | 1978-08-15 | Glaxo Laboratories Limited | Δ3 -3-Vinyl or substituted vinyl-4-carboxy cephalosporins |
US4110534A (en) * | 1970-01-23 | 1978-08-29 | Glaxo Laboratories Limited | Process for the preparation of 3-vinyl and substituted vinyl cephalosporins |
US4065620A (en) * | 1971-06-14 | 1977-12-27 | Eli Lilly And Company | 3-(Substituted) vinyl cephalosporins |
FR2540117A1 (fr) * | 1983-01-28 | 1984-08-03 | Bristol Myers Co | Vinylcephalosporines substituees |
US4520022A (en) * | 1983-01-28 | 1985-05-28 | Bristol-Myers Company | Substituted vinyl cephalosporins |
GB2173798A (en) * | 1985-04-22 | 1986-10-22 | Bristol Myers Co | Cephalosporanic acid derivatives |
GB2178032A (en) * | 1985-06-24 | 1987-02-04 | Bristol Myers Co | Cephalosporanic acid derivatives |
US4694079A (en) * | 1985-07-29 | 1987-09-15 | Bristol-Myers Company | 3-propenyl cephalosporin solvates |
US4727070A (en) * | 1985-11-25 | 1988-02-23 | Bristol-Myers Company | 3-Propenzl cephalosporin isomer separation process and derivative |
US4847373A (en) * | 1987-02-26 | 1989-07-11 | Bristol-Myers Company | Production of 3-allyl- and 3-butenyl-3-cephems |
EP0292806A2 (de) * | 1987-05-26 | 1988-11-30 | Bayer Ag | Substituierte Vinylcephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP0304036A2 (en) * | 1987-08-17 | 1989-02-22 | Bristol-Myers Squibb Company | 3-(substituted)propenyl-7-(aminothiazolylacetamido)ceph-3-em-4-carboxylic acids and esters thereof |
EP0355821A2 (en) * | 1988-08-23 | 1990-02-28 | Bristol-Myers Squibb Company | A process for preparing cephem prodrug esters |
EP0421219A2 (de) * | 1989-10-03 | 1991-04-10 | Bayer Ag | Verfahren zur Herstellung von 7-Amino-3-[(Z)-1-propen-1-yl]-3-cephem-4-carbonsäure |
US5132419A (en) * | 1989-10-03 | 1992-07-21 | Bayer Aktiengesellschaft | Process for the preparation of 7-amino-3-((z)-1-propen-1yl)-3-cephem-4-carboxylic acid |
EP0472060A2 (en) * | 1990-08-23 | 1992-02-26 | Bristol-Myers Squibb Company | Antibiotic c-7 catechol-subtituted cephalosporin compounds, compositions, and use thereof |
EP0503453A2 (en) * | 1991-03-08 | 1992-09-16 | Biochemie Gesellschaft M.B.H. | New process for the production of cephalosporines and novel intermediates in this process |
Non-Patent Citations (6)
Title |
---|
J. Org. Chem., 29 (1964) Nov. 1964 Wittig Reaction with Stabilized Y Lids pp. 3327 3333. * |
J. Org. Chem., 29 (1964) Nov. 1964 Wittig Reaction with Stabilized Y Lids--pp. 3327-3333. |
Pharmacopeial Forum vol. 18, No. 4 Jul. Aug. 1992 pp. 3635 3637. * |
Pharmacopeial Forum--vol. 18, No. 4 Jul.-Aug. 1992--pp. 3635-3637. |
The Journal of Antiobiotics Dec. 1990 pp. 1564 1572. * |
The Journal of Antiobiotics Dec. 1990--pp. 1564-1572. |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6350869B1 (en) * | 1997-04-04 | 2002-02-26 | Biochemie Gesellschaft M.B.H. | Crystalline amine salt of cefdinir |
US7250508B2 (en) | 2002-08-13 | 2007-07-31 | Sandoz Ag | Cefdinir intermediate |
US20080081906A1 (en) * | 2002-08-13 | 2008-04-03 | Peter Kremminger | cefdinir intermediate |
US7825241B2 (en) | 2002-08-13 | 2010-11-02 | Sandoz Ag | Cefdinir intermediate |
US20060025586A1 (en) * | 2002-08-13 | 2006-02-02 | Peter Kremminger | Cefdinir intermediate |
WO2004033464A1 (en) * | 2002-10-08 | 2004-04-22 | Ranbaxy Laboratories Limited | Process for the preparation of (z)-isomer enriched 7-amino-3-propen-1-yl-3-cephem-4- carboxylic acid |
US20060173176A1 (en) * | 2002-10-08 | 2006-08-03 | Yatendra Kumar | Process for the preparation of (z)-isomer enriched 7-amino-3-propen-1-yl-3-cephem-4-carboxylic acid |
CN100343259C (zh) * | 2002-10-30 | 2007-10-17 | 幽兰化学医药有限公司 | 制备3-丙烯基头孢菌素dmf溶剂化物的方法 |
WO2004039812A1 (en) * | 2002-10-30 | 2004-05-13 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of 3-propenyl cephalosporin dmf solvate |
US20070270586A1 (en) * | 2003-03-24 | 2007-11-22 | Eiji Imai | Novel crystal of 7-[2-[(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof |
WO2005100369A1 (en) * | 2004-04-13 | 2005-10-27 | Ranbaxy Laboratories Limited | Depletion of e-isomers in preparation of z-enriched 3-(2-substituted vinyl) cephalosporins |
US20060122165A1 (en) * | 2004-12-07 | 2006-06-08 | Otto Daemon | Crystalline cefdinir |
US20070128268A1 (en) * | 2005-12-07 | 2007-06-07 | Herwig Jennewein | Pharmaceutical compositions comprising an antibiotic |
US20090176755A1 (en) * | 2005-12-07 | 2009-07-09 | Herwig Jennewein | Pharmaceutical compositions comprising an antibiotic |
US20110225507A1 (en) * | 2010-03-15 | 2011-09-15 | Gmc Software Ag | Method and devices for generating two-dimensional visual objects |
US9189460B2 (en) * | 2010-03-15 | 2015-11-17 | Gmc Software Ag | Method and devices for generating two-dimensional visual objects |
US10049478B2 (en) | 2010-03-15 | 2018-08-14 | Quadient Group Ag | Retrieval and display of visual objects |
Also Published As
Publication number | Publication date |
---|---|
DK0630380T3 (da) | 2001-12-10 |
ATE205214T1 (de) | 2001-09-15 |
KR950700311A (ko) | 1995-01-16 |
DE69232048D1 (de) | 2001-10-11 |
EP1103555A1 (en) | 2001-05-30 |
JPH07503474A (ja) | 1995-04-13 |
EP0630380A1 (en) | 1994-12-28 |
US6333409B1 (en) | 2001-12-25 |
DE69232048T2 (de) | 2002-07-04 |
GR3036985T3 (en) | 2002-01-31 |
WO1993016084A1 (en) | 1993-08-19 |
US6136967A (en) | 2000-10-24 |
EP0630380B1 (en) | 2001-09-05 |
ES2162812T3 (es) | 2002-01-16 |
EP1103555B1 (en) | 2003-11-05 |
CA2124322C (en) | 2007-04-17 |
DE69233249D1 (de) | 2003-12-11 |
ATE253583T1 (de) | 2003-11-15 |
ES2210047T3 (es) | 2004-07-01 |
SG48415A1 (en) | 1998-04-17 |
TW230775B (ru) | 1994-09-21 |
CA2124322A1 (en) | 1993-08-19 |
PT630380E (pt) | 2002-02-28 |
DE69233249T2 (de) | 2004-08-19 |
JP2825655B2 (ja) | 1998-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5869648A (en) | Process for the purification of a 3-cephem-4-carboxylic acid derivative | |
US5616703A (en) | Separation of cephalosporin isomers | |
AU731265B2 (en) | A process for the selective preparation of z-isomers of a 3-(2-substituted vinyl-)-cephalosporin | |
US6835829B2 (en) | Purification process | |
JP3751880B2 (ja) | 高純度セフポドキシムプロキセチルの製造方法 | |
EP1029864A1 (en) | Process for the purification of a 3-cephem-4-carboxylic acid derivative | |
US7622577B2 (en) | Processes for the preparation of cephalosporin derivatives | |
US4237280A (en) | Intermediate for cephalosporin type compound | |
KR100213444B1 (ko) | 세펨 유도체의 새로운 제조방법 | |
US5026842A (en) | Process for preparing cephalosporin compounds | |
EP0382220A2 (en) | Method for preparing aminothiazolylacetic acid derivatives | |
KR20030067764A (ko) | 세팔로스포린 화합물의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: BIOCHEMIE GESELLSCHAFT M.B.H., AUSTRIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LUDESCHER, JOHANNES;PRAGER, BERNHARD;WOLF, SIEGFRIED;REEL/FRAME:009572/0234 Effective date: 19940504 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20070209 |